Circulating Tumor DNA–Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL).Materials and Methods After targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.Results Plasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.Conclusion Our results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.
Abstract
Purpose Plasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL).Materials and Methods After targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.Results Plasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.Conclusion Our results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.
참고문헌 (30)
- Vose J, "International peripheral T-cell and natural killer", T-cell lymphoma study : pathology findings and clinical outcomes, 2008, pp.26, 4124~4130
- Briski R, "The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas", Blood Cancer J, 4, pp.e214~ (2014)
- Ellin F, "Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas : a study from the Swedish Lymphoma Registry", Blood, 124, pp.1570~1577 (2014)
- Phan A, "T-cell lymphoma epidemiology : the known and unknown", Curr Hematol Malig Rep, 11, pp.492~503 (2016)
- Ma H, "The peripheral T-cell lymphomas : an unusual path to cure", Lancet Haematol, 7, pp.e765~71 (2020)
- Cirillo M, "Liquid biopsy in lymphoma : molecular methods and clinical applications", Cancer Treat Rev, 91, pp.102106~ (2020)
- Dogliotti I, "New molecular technologies for minimal residual disease evaluation in B-cell lymphoid malignancies", J Clin Med, 7, pp.288~ (2018)
- Camus V, "Cell-free DNA and the monitoring of lymphoma treatment", Pharmacogenomics, 20, pp.1271~1282 (2019)
- Kurtz DM, "Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma", J Clin Oncol, 36, pp.2845~2853 (2018)
- Qi F, "Liquid biopsy in extranodal NK", T-cell lymphoma : a prospective analysis of cell-free DNA genotyping and monitoring, 2021, pp.5, 2505~2514
- Miljkovic MD, "Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL", Blood Adv, 5, pp.4198~4210 (2021)
- Zhang W, "Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas", Int J Lab Hematol, 43, pp.1041~1049 (2021)
- Sakata-Yanagimoto M, "Detection of the circulating tumor DNAs in angioimmunoblastic T-cell lymphoma", Ann Hematol, 96, pp.1471~1475 (2017)
- Shin SH, "Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes", Leuk Lymphoma, 60, pp.2237~2246 (2019)
- Hur JY, "Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas", Ann Hematol, 99, pp.1293~1302 (2020)
- Cheson BD, "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma : the Lugano classification", J Clin Oncol, 32, pp.3059~3068 (2014)
- Newman AM, "Integrated digital error suppression for improved detection of circulating tumor DNA", Nat Biotechnol, 34, pp.547~555 (2016)
- McKenna A, "The Genome Analysis Toolkit : a MapReduce framework for analyzing next-generation DNA sequencing data", Genome Res, 20, pp.1297~1303 (2010)
- Li H, "A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data", Bioinformatics, 27, pp.2987~2993 (2011)
- Avanzini S, "A mathematical model of ctDNA shedding predicts tumor detection size", Sci Adv, 6, pp.eabc4308~ (2020)
- Sakata-Yanagimoto M, "Somatic RHOA mutation in angioimmunoblastic T cell lymphoma", Nat Genet, 46, pp.171~175 (2014)
- Yoo HY, "A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma", Nat Genet, 46, pp.371~375 (2014)
- Palomero T, "Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas", Nat Genet, 46, pp.166~170 (2014)
- Swerdlow SH, "The 2016 revision of the World Health Organization classification of lymphoid neoplasms", Blood, 127, pp.2375~2390 (2016)
- Lemonnier F, "Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma", Blood Adv, 5, pp.539~548 (2021)
- Heavican TB, "Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma", Blood, 133, pp.1664~1676 (2019)
- Ji MM, "Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified", Haematologica, 103, pp.679~687 (2018)
- Xie C, "Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma", Exp Hematol Oncol, 9, pp.30~ (2020)
- Melchardt T, "Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones", Oncotarget, 7, pp.51494~51502 (2016)
- Pon JR, "MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation", Nat Commun, 6, pp.7953~ (2015)